Athira Pharma(ATHA) - 2025 Q1 - Quarterly Results

Exhibit 99.1 Athira Pharma Reports First Quarter 2025 Financial Results and Pipeline and Business Updates Completed healthy volunteer Phase 1 clinical study of ATH-1105 as a potential treatment for amyotrophic lateral sclerosis (ALS); full healthy volunteer data expected in 2H25 On-track to enable dosing ALS patients in late 2025 BOTHELL, Wash., May 9, 2025 – Athira Pharma, Inc. (NASDAQ: ATHA), a clinical stage biopharmaceutical company focused on developing small molecules to restore neuronal health and sl ...